YehudaEDeutschMD

Physician

Dr. Deutsch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
603 N Flamingo Rd
Ste 151
Pembroke Pines, FL 33028
Phone+1 954-265-4325

Fax+1 954-436-4606

University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2009 - 2012
University of Miami Leonard M. Miller School of MedicineClass of 2009

PubMed

4 citations
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball
Blood Advances. 2024-03-12
11 citations
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, Wassim Samra, Justin M Watts
Cancer. 2022-11-01
7 citations
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Dasom Lee, Akriti G Jain, Yehuda Deutsch, Jennifer Eatrides, Onyee Chan
Clinical Lymphoma, Myeloma & Leukemia. 2022-10-01

Abstracts/Posters

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
Yehuda E. Deutsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
Yehuda E. Deutsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Yehuda E. Deutsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Yehuda E. Deutsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018